MXPA02005139A - Peptidos n-alquilados que tienen actividad antiangiogenica. - Google Patents

Peptidos n-alquilados que tienen actividad antiangiogenica.

Info

Publication number
MXPA02005139A
MXPA02005139A MXPA02005139A MXPA02005139A MXPA02005139A MX PA02005139 A MXPA02005139 A MX PA02005139A MX PA02005139 A MXPA02005139 A MX PA02005139A MX PA02005139 A MXPA02005139 A MX PA02005139A MX PA02005139 A MXPA02005139 A MX PA02005139A
Authority
MX
Mexico
Prior art keywords
alkylated peptides
antiangiogenic activity
angiogenesis
inhibiting
alkylated
Prior art date
Application number
MXPA02005139A
Other languages
English (en)
Inventor
M Kalvin Douglas
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MXPA02005139A publication Critical patent/MXPA02005139A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los peptidos N-alquilados de la formula (I) Xaa1- Xaa2- Xaa3- Xaa4- Xaa5- Xaa6- Xaa7- Xaa8- Xaa9- Xaa10- Xaa11-, son utiles en la inhibicion de angiogenesis. Tambien se exponen composiciones inhibidoras de angiogenesis y metodos para inhibir la angiogenesis en un mamifero.
MXPA02005139A 1999-11-22 2000-11-22 Peptidos n-alquilados que tienen actividad antiangiogenica. MXPA02005139A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44709999A 1999-11-22 1999-11-22
US70264900A 2000-10-31 2000-10-31
PCT/US2000/032105 WO2001038397A1 (en) 1999-11-22 2000-11-22 N-alkylated peptides having antiangiogenic activity

Publications (1)

Publication Number Publication Date
MXPA02005139A true MXPA02005139A (es) 2004-08-23

Family

ID=27034850

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005139A MXPA02005139A (es) 1999-11-22 2000-11-22 Peptidos n-alquilados que tienen actividad antiangiogenica.

Country Status (10)

Country Link
EP (1) EP1242455A1 (es)
JP (1) JP2003514920A (es)
AR (1) AR026901A1 (es)
AU (1) AU1791301A (es)
BR (1) BR0010934A (es)
CA (1) CA2386893A1 (es)
CO (1) CO5261544A1 (es)
HK (1) HK1050902A1 (es)
MX (1) MXPA02005139A (es)
WO (1) WO2001038397A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183242A1 (en) * 2001-04-11 2002-12-05 Jack Henkin Peptide antiangiogenic drugs
US20030119746A1 (en) * 2001-10-31 2003-06-26 Fortuna Haviv Hepta-and octapeptides having antiangiogenic activity
US7037897B2 (en) 2001-10-31 2006-05-02 Abbott Laboratories TRI-, TETRA-, and penta-peptides having antiangiogenic activity
US7122625B2 (en) 2001-10-31 2006-10-17 Abbott Laboratories Hexa-, hepta-, and octapeptides having antiangiogenic activity
US20030125259A1 (en) 2001-10-31 2003-07-03 Fortuna Haviv Octa- and nonapeptides having antiangiogenic activity
US7067490B2 (en) 2001-10-31 2006-06-27 Abbott Laboratories Hepta-, Octa-and nonapeptides having antiangiogenic activity
US7169888B2 (en) 2001-10-31 2007-01-30 Abbott Laboratories Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity
US7001984B2 (en) 2001-10-31 2006-02-21 Abbott Laboratories Di-, tri-, and tetra-peptides having antiangiogenic activity
US20030228365A1 (en) * 2002-06-07 2003-12-11 Fortuna Haviv Pharmaceutical formulation
WO2006094269A2 (en) 2005-03-03 2006-09-08 Covx Technologies Ireland Limited Anti-angiogenic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033174A1 (en) * 1996-03-05 1997-09-12 Torrey Pines Institute For Molecular Studies Selectively n-alkylated peptidomimetic combinatorial libraries and compounds therein
EP0910571B1 (en) * 1996-05-03 2005-07-20 Abbott Laboratories Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis
DE69827223T2 (de) * 1997-03-17 2006-02-02 Northwestern University, Chicago Antiangiogene substanz zur behandlung von krebs, arthritis und netzhauterkrankungen

Also Published As

Publication number Publication date
CA2386893A1 (en) 2001-05-31
CO5261544A1 (es) 2003-03-31
AR026901A1 (es) 2003-03-05
WO2001038397A1 (en) 2001-05-31
AU1791301A (en) 2001-06-04
HK1050902A1 (zh) 2003-07-11
EP1242455A1 (en) 2002-09-25
JP2003514920A (ja) 2003-04-22
BR0010934A (pt) 2002-12-17

Similar Documents

Publication Publication Date Title
MXPA02005139A (es) Peptidos n-alquilados que tienen actividad antiangiogenica.
PE20060713A1 (es) Polipeptidos moduladores del peptido 1 similar al glucagon humano
WO2002000067A3 (de) Halterung zum präsentieren mindestens eines länglichen mehrzweck-handgeräts
HK1060519A1 (en) Compositions containing alpha-2-adrenergic agonist components
AR070809A1 (es) Conjugados antagonistas peptidicos analogos a la bombesina
AP2001002063A0 (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists.
GB2411467A (en) Method and apparatus for quantifying tissue histology
AU3677900A (en) Agent for improving ketosis
AR071262A2 (es) Peptidos derivados de una proteina de vih-1gagp24, composiciones de vacunas kit de inmunoensayo y un metodo para detectar anticuerpos inducidos por vih
AU2002237715A1 (en) System for package loading and methods for package handling
GB2408609A (en) Modular financial service instrument
SG132670A1 (en) Methods and systems for handling workpieces in a vacuum-based semiconductor handling system
HK1053473A1 (en) Inhibitors of alpha-l beta-2 mediated cell adhesion.
AR030245A1 (es) Composiciones de gel que contienen metronidazol
CO5700728A2 (es) Composiciones, metodos y sistemas antisepticos
AU2001282775A1 (en) A method and a system for handling pieces of wood
BR0000268A (pt) Método para controlar chamada em comunicação móvel e, sistema para este método
WO2001081417A3 (en) Use of taci as an anti-tumor agent
CA2554795A1 (en) System and method of polling electronic mailboxes
WO2003105767A3 (en) ANTIFUNGAL PARENTERAL PRODUCTS
AU7988300A (en) Guide rail support bracket for conveyor system
PL311698A1 (en) Preparations in the form of solid solutions
GB2419837A (en) Magnetic rotary die
AU7500400A (en) Autologous marrow stem cell (msc) transplantation for myocardial regeneration
CA2361534A1 (en) Alpha-conotoxin peptides

Legal Events

Date Code Title Description
FA Abandonment or withdrawal